Dec 08, 2017 7:05pm EST Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
Dec 08, 2017 7:30am EST Rigel to Present One-Year Efficacy and Safety Results for Fostamatinib in ITP at the 2017 American Society of Hematology Annual Meeting
Nov 17, 2017 4:05pm EST Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Nov 07, 2017 4:01pm EST Rigel Announces Third Quarter 2017 Financial Results and Provides Company Update
Oct 31, 2017 7:30am EDT Rigel Announces Conference Call and Webcast to Report Third Quarter 2017 Financial Results
Oct 10, 2017 4:01pm EDT Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares
Oct 03, 2017 7:30am EDT Fostamatinib Meets Pre-Specified Primary Endpoint in Stage 1 of Autoimmune Hemolytic Anemia (AIHA) Phase 2 Study
